CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 1, 2004, Pages 143-155

  Cummins, Carolyn L ^a,b   Jacobsen, Wolfgang ^a,c   Christians, Uwe ^a,d   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYMIDAZOLAM; 11 HYDROXYSIROLIMUS; 12 HYDROXYSIROLIMUS; 39 O NORSIROLIMUS; 4 HYDROXYMIDAZOLAM; ANESTHETIC AGENT; CYCLOSPORIN A; CYTOCHROME P450 3A4; DRUG METABOLITE; ELACRIDAR; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MIDAZOLAM; RAPAMYCIN; UNCLASSIFIED DRUG;

ABSORPTION; ABSORPTION RATE; ANIMAL CELL; ARTICLE; BIOCHEMICAL ABSORPTION BARRIER; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG METABOLISM; DRUG TRANSPORT; EXTRACTION RATIO; GENETIC TRANSFECTION; IN VITRO STUDY; KINETICS; LIVER MICROSOME; NONHUMAN; PERMEABILITY BARRIER; PREDICTION; PRIORITY JOURNAL;

ABSORPTION; ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDAZOLAM; SIROLIMUS; TRANSFECTION;

EID: 0345866819     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.058065     Document Type: Article

References (28)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Arceci RJ, Stieglitz K, and Bierer BE (1992) Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80:1528-1536.
3. Artursson P and Borchardt RT (1997) Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res (NY) 14:1655-1658.
4. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880-885.
5. Benet LZ, Kroetz DL, and Sheiner LB (1996a) The dynamics of drug absorption, distribution and elimination., in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, and Gilman AG eds) pp 3-28, McGraw-Hill Companies, New York.
6. Benet LZ, Wu CY, Hebert MF, and Wacher VJ (1996b) Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Release 39:139-143.
7. Christians U, Jacobsen W, Serkova N, Benet LZ, Vidal C, Sewing KF, Manns MP, and Kirchner GI (2000) Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 748:41-53.
8. Crowe A, Bruelisauer A, Duerr L, Guntz P, and Lemaire M (1999) Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 27:627-632.
9. Crowe A and Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res (NY) 15:1666-1672.
10. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
11. Cummins CL, Mangravite LM and Benet LZ (2001) Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1 and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res (NY) 18:1102-1109.
12. Dias VC and Yatscoff RW (1994) Investigation of rapamycin transport and uptake across absorptive human intestinal cell monolayers. Clin Biochem 27:31-36.
13. Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, and Thummel KE (1999) First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 289:1134-1142.
14. Hallensleben K, Raida M, and Habermehl G (2000) Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom 11:516-525.
15. Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, and Christians U (2001) Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 33:514-515.
16. Kaplan B, Meier-Kriesche HU, Napoli KL, and Kahan BD (1998) The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 63:48-53.
17. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
18. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, and Christians U (1998) Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285:1104-1112.
19. Paine MF, Leung LY, Lim HK, Liao K, Oganesian A, Zhang MY, Thummel KE, and Watkins PB (2002) Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther 301:174-186.
20. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
21. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
22. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, and Watkins PB (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 51:741-754.
23. Streit F, Christians U, Schiebel HM, Napoli KL, Ernst L, Linck A, Kahan BD, and Sewing KF (1996) Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 42:1417-1425.
24. Tolle-Sander S, Rautio J, Wring S, Polli JW, and Polli JE (2003) Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res (NY) 20:757-764.
25. Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'Mahony D, and Ramtoola Z (2002) Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther 303:308-313.
26. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
27. Wang CP, Chan KW, Schiksnis RA, Scatina J, and Sisenwine SF (1994) High performance liquid chromatographic isolation, spectroscopic characterization and immunosuppressive activities of two rapamycin degradation products. J Liq Chromatogr 17:3383-3392.
28. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res (NY) 14:763-766.